TUCSON, Ariz. , Dec. 03, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that it will host a Key Opinion Leader (KOL) luncheon at 12:00 pm ET on Friday, December 13 th in Boston,
HTG EdgeSeq Reveal software version 2.0.0 streamlines data analysis process and enhances user experience TUCSON, Ariz. , Nov. 19, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, yesterday
Product and product-related services revenue increased by 228% and 125% in the three and nine-month periods, respectively, compared to the prior year periods Call scheduled for today, November 12 , at 4:30pm ET TUCSON, Ariz. , Nov. 12, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc.
TUCSON, Ariz. , Oct. 31, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM), a diagnostic company whose mission is to advance precision medicine, today announced that it will report its financial results for the third quarter ended September 30, 2019 after the market close on
TUCSON, Ariz. , Oct. 22, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) , a diagnostic company whose mission is to advance precision medicine, today announced that it will host a Key Opinion Leader (KOL) luncheon at 12:00 pm ET on Tuesday, October 29 th in New York City .
TUCSON, Ariz. , Oct. 15, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today announced it will begin taking orders for its new 2,002-gene HTG EdgeSeq Autoimmune Panel, which is expected to be
TUCSON, Ariz. , Oct. 10, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today provided an update regarding its ongoing efforts related to the development, manufacture and commercialization of
TUCSON, Ariz. , Sept. 30, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today announced that John Lubniewski , President and CEO, will present a corporate overview at the Cantor 2019 Global
TUCSON, Ariz. , Sept. 24, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today announced the completion of its previously announced underwritten public offering of 29,298,537 shares of its common
TUCSON, Ariz. --(BUSINESS WIRE)--Sep. 20, 2019-- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today announced the pricing of an underwritten public offering of 25,476,989 shares of its common stock at a price to the
